Re: Androgen deprivation therapy and radiotherapy in intermediate risk prostate cancer: A randomized phase III trial
- PMID: 35282967
- DOI: 10.1016/j.ejca.2022.01.041
Re: Androgen deprivation therapy and radiotherapy in intermediate risk prostate cancer: A randomized phase III trial
Conflict of interest statement
Conflict of interest statement The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Comment in
-
Reply to comment on: Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial.Eur J Cancer. 2022 May;167:166-167. doi: 10.1016/j.ejca.2022.01.042. Epub 2022 Mar 18. Eur J Cancer. 2022. PMID: 35314114 No abstract available.
Comment on
-
Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial.Eur J Cancer. 2021 Jan;143:64-74. doi: 10.1016/j.ejca.2020.10.023. Epub 2020 Dec 3. Eur J Cancer. 2021. PMID: 33279855 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
